MA35507B1 - Protéines à double fonction pour le traitement de troubles du métabolisme - Google Patents
Protéines à double fonction pour le traitement de troubles du métabolismeInfo
- Publication number
- MA35507B1 MA35507B1 MA36823A MA36823A MA35507B1 MA 35507 B1 MA35507 B1 MA 35507B1 MA 36823 A MA36823 A MA 36823A MA 36823 A MA36823 A MA 36823A MA 35507 B1 MA35507 B1 MA 35507B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- metabolic disorders
- dual function
- metabolic
- related disorders
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'identification de protéines de nouvelles protéines comprenant le facteur de croissance des fibroblastes 21 (fgf21) et d'autres régulateurs du métabolisme, y compris des variants de ceux-ci, connus pour améliorer les profils métaboliques chez des sujets auxquels ils sont administrés. L'invention concerne également des procédés de traitement de troubles associés au fgf21, de troubles associés au glp-1 et de troubles associés à l'exendine-4, y compris des troubles du métabolisme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539290P | 2011-09-26 | 2011-09-26 | |
| PCT/US2012/057371 WO2013049234A2 (fr) | 2011-09-26 | 2012-09-26 | Protéines à double fonction pour le traitement de troubles du métabolisme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35507B1 true MA35507B1 (fr) | 2014-10-02 |
Family
ID=47023090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36823A MA35507B1 (fr) | 2011-09-26 | 2014-03-13 | Protéines à double fonction pour le traitement de troubles du métabolisme |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9458214B2 (fr) |
| EP (1) | EP2764019B1 (fr) |
| JP (1) | JP6152380B2 (fr) |
| KR (1) | KR102217254B1 (fr) |
| CN (2) | CN104024273B (fr) |
| AP (1) | AP2014007544A0 (fr) |
| AR (1) | AR088165A1 (fr) |
| AU (1) | AU2012316132A1 (fr) |
| BR (1) | BR112014007086A2 (fr) |
| CA (1) | CA2849760A1 (fr) |
| CL (1) | CL2014000737A1 (fr) |
| CO (1) | CO6920258A2 (fr) |
| CR (1) | CR20140141A (fr) |
| CU (1) | CU20140035A7 (fr) |
| EA (1) | EA201490697A1 (fr) |
| GT (1) | GT201400056A (fr) |
| IL (1) | IL231647A0 (fr) |
| MA (1) | MA35507B1 (fr) |
| MX (1) | MX350840B (fr) |
| PE (1) | PE20141542A1 (fr) |
| SG (1) | SG11201400596QA (fr) |
| TN (1) | TN2014000110A1 (fr) |
| TW (1) | TW201315742A (fr) |
| UY (1) | UY34347A (fr) |
| WO (1) | WO2013049234A2 (fr) |
| ZA (1) | ZA201401699B (fr) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578205A1 (fr) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale |
| HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| EP2791160B1 (fr) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Compositions de mrna modifiés |
| AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| KR102238317B1 (ko) | 2012-05-17 | 2021-04-12 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
| TW201420606A (zh) * | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| AU2013311777B2 (en) * | 2012-09-07 | 2018-02-01 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| EP2922554B1 (fr) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Arn terminale modifiés |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| DK2938740T3 (da) | 2012-12-27 | 2022-06-20 | Ngm Biopharmaceuticals Inc | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| EP2941267B1 (fr) * | 2013-01-03 | 2022-11-16 | Oramed Ltd. | Compositions pour l'utilisation dans le traitement de la stéatopathie hépatique non alcoolique |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| SG11201602870YA (en) | 2013-10-28 | 2016-05-30 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| UA119863C2 (uk) | 2014-01-24 | 2019-08-27 | Нгм Біофармасьютікалс, Інк. | Антитіло або його фрагмент, що зв'язується з бета-клото |
| JP6712230B2 (ja) * | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| PT3129467T (pt) * | 2014-04-11 | 2020-02-04 | Univ Catholique Louvain | Ilhéus de porco transgénicos e seus usos para tratar a diabetes |
| WO2015183890A2 (fr) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
| AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EA037478B1 (ru) | 2015-08-04 | 2021-04-01 | Дьюк Юниверсити | Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102670157B1 (ko) * | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| CA3010756A1 (fr) | 2016-01-13 | 2017-07-20 | Novo Nordisk A/S | Analogues d'egf(a) avec substituants acides gras |
| US11318186B2 (en) | 2016-05-25 | 2022-05-03 | Board Of Regents, The University Of Texas System | Use of FGF21 in methods of increasing exocrine pancreatic secretion |
| WO2017210476A1 (fr) | 2016-06-01 | 2017-12-07 | Duke University | Biocapteurs ne s'encrassant pas |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| US11135301B2 (en) | 2016-09-14 | 2021-10-05 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
| JP2020500150A (ja) | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
| US11179440B2 (en) | 2016-11-10 | 2021-11-23 | Yuhan Corporation | Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis |
| AU2017363321B2 (en) | 2016-11-22 | 2023-09-28 | Klotho Therapeutics, Inc. | Novel recombinant Klotho proteins and compositions and methods involving the same |
| CA3047862A1 (fr) * | 2016-12-22 | 2018-06-28 | Sanofi | Combinaisons d'agonistes du compose fgf21/agoniste du glp-1r ayant un rapport d'activite optimise |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
| US20220127322A1 (en) * | 2017-03-14 | 2022-04-28 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| US11560416B2 (en) * | 2017-04-21 | 2023-01-24 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
| JP7339236B2 (ja) | 2017-07-19 | 2023-09-05 | ノヴォ ノルディスク アー／エス | 二機能性化合物 |
| EP3706774A4 (fr) * | 2017-11-06 | 2021-09-08 | Shire-NPS Pharmaceuticals, Inc. | Analogues de glp-2 et peptibodies destinés à être administrés avant, pendant ou après une intervention chirurgicale |
| CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
| CN111518770B (zh) * | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
| IL275499B2 (en) * | 2017-12-22 | 2024-03-01 | Novartis Ag | Methods for treating metabolic disorders with FGF21 variants |
| CN110028587B (zh) * | 2018-01-11 | 2021-10-08 | 安源医药科技（上海）有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
| US11679143B2 (en) | 2018-02-08 | 2023-06-20 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| JP2021528422A (ja) * | 2018-06-21 | 2021-10-21 | サノフイＳａｎｏｆｉ | 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ |
| EP3817720A2 (fr) | 2018-07-03 | 2021-05-12 | Bristol-Myers Squibb Company | Formulations de fgf21 |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| EP3927815A2 (fr) * | 2019-02-20 | 2021-12-29 | Novo Nordisk A/S | Aminoacyl-arnt synthétases et leurs utilisations |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021139744A1 (fr) * | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugués de protéines de fusion du glp-1 et du fgf21 |
| US11981718B2 (en) * | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
| WO2024102634A1 (fr) * | 2022-11-07 | 2024-05-16 | Bp Asset Ix, Inc. | Variant de protéine fgf21 pour le traitement de la nash |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
| EP0587255A1 (fr) | 1986-05-05 | 1994-03-16 | The General Hospital Corporation | Hormone insulinotropique |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| CA2006596C (fr) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | G-csf modifie chimiquement |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| ATE446365T1 (de) | 1999-11-18 | 2009-11-15 | Novartis Vaccines & Diagnostic | Menschliches fgf-21 gen und genexpressionsprodukte |
| DE60030769T2 (de) | 1999-12-23 | 2007-10-25 | Zymogenetics, Inc., Seattle | Verfahren zur behandlung von entzündungen |
| JP2005502322A (ja) | 2001-04-19 | 2005-01-27 | ザ スクリップス リサーチ インスティテュート | 非天然アミノ酸のインビボ組込み |
| ATE522548T1 (de) * | 2003-11-13 | 2011-09-15 | Hanmi Holdings Co Ltd | Verfahren zur massenproduktion der konstanten region von immunglobulin |
| BRPI0416683A (pt) * | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
| EP1797127B1 (fr) * | 2004-09-24 | 2017-06-14 | Amgen Inc. | Molecules fc modifiees |
| EP1846019A2 (fr) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Methode de traitement de maladie cardio-vasculaire |
| EP2068909B1 (fr) | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Polypeptides fgf-21 modifies, et leurs utilisations |
| WO2009020802A2 (fr) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Traitement de l'obésité |
| EA201990619A1 (ru) | 2008-10-10 | 2019-07-31 | Амген Инк. | Fgf21 мутанты и их применение |
| ES2477543T3 (es) | 2008-10-24 | 2014-07-17 | Irm Llc | Pirrolina-carboxi-lisina generada biosintéticamente y modificaciones de proteínas específicas de sitio mediante derivatización química de restos de pirrolina-carboxi-lisina y pirrolisina |
| WO2010065439A1 (fr) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants de facteurde croissance 21 du fibroblaste |
| HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
| BRPI1007313A2 (pt) | 2009-01-23 | 2016-02-10 | Novo Nordisk As | derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso. |
| CN101812474A (zh) * | 2009-02-25 | 2010-08-25 | 李慎涛 | 骨保护素-热休克蛋白65融合蛋白的制备及其应用 |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| US8188040B2 (en) | 2009-05-05 | 2012-05-29 | Amgen Inc. | FGF21 mutants and uses thereof |
| CN102802657A (zh) | 2009-06-11 | 2012-11-28 | 诺沃-诺迪斯克有限公司 | 用于治疗2型糖尿病的glp-1和fgf21组合 |
| CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| CN101993496B (zh) * | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
| KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| EP2460527A1 (fr) | 2010-01-21 | 2012-06-06 | Sanofi | Composition pharmaceutique pour le traitement d'un syndrome métabolique |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
-
2012
- 2012-09-25 TW TW101135181A patent/TW201315742A/zh unknown
- 2012-09-25 UY UY0001034347A patent/UY34347A/es not_active Application Discontinuation
- 2012-09-25 US US13/626,207 patent/US9458214B2/en active Active
- 2012-09-26 AU AU2012316132A patent/AU2012316132A1/en not_active Abandoned
- 2012-09-26 AP AP2014007544A patent/AP2014007544A0/xx unknown
- 2012-09-26 SG SG11201400596QA patent/SG11201400596QA/en unknown
- 2012-09-26 EP EP12773169.3A patent/EP2764019B1/fr active Active
- 2012-09-26 CN CN201280057819.0A patent/CN104024273B/zh active Active
- 2012-09-26 AR ARP120103552A patent/AR088165A1/es unknown
- 2012-09-26 KR KR1020147010943A patent/KR102217254B1/ko active IP Right Grant
- 2012-09-26 JP JP2014532112A patent/JP6152380B2/ja not_active Expired - Fee Related
- 2012-09-26 EA EA201490697A patent/EA201490697A1/ru unknown
- 2012-09-26 MX MX2014003676A patent/MX350840B/es active IP Right Grant
- 2012-09-26 WO PCT/US2012/057371 patent/WO2013049234A2/fr active Application Filing
- 2012-09-26 BR BR112014007086A patent/BR112014007086A2/pt not_active Application Discontinuation
- 2012-09-26 CN CN201610821947.8A patent/CN106432510A/zh active Pending
- 2012-09-26 CA CA2849760A patent/CA2849760A1/fr not_active Abandoned
- 2012-09-26 PE PE2014000419A patent/PE20141542A1/es not_active Application Discontinuation
-
2014
- 2014-03-07 ZA ZA2014/01699A patent/ZA201401699B/en unknown
- 2014-03-12 TN TNP2014000110A patent/TN2014000110A1/en unknown
- 2014-03-13 MA MA36823A patent/MA35507B1/fr unknown
- 2014-03-20 IL IL231647A patent/IL231647A0/en unknown
- 2014-03-25 CL CL2014000737A patent/CL2014000737A1/es unknown
- 2014-03-26 CU CU2014000035A patent/CU20140035A7/es unknown
- 2014-03-26 GT GT201400056A patent/GT201400056A/es unknown
- 2014-03-26 CR CR20140141A patent/CR20140141A/es unknown
- 2014-03-26 CO CO14064524A patent/CO6920258A2/es unknown
-
2016
- 2016-08-26 US US15/248,712 patent/US10669323B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35507B1 (fr) | Protéines à double fonction pour le traitement de troubles du métabolisme | |
| MA35437B1 (fr) | Proteines de fusion pour le traitement de troubles du metabolisme | |
| MA34710B1 (fr) | Procede de traitement des troubles associes au fgf21 | |
| EA200700886A1 (ru) | Соединение тиадиазола и его применение | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| MY164376A (en) | Phosphospecific antibodies recognizing tau | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| MY171300A (en) | Pharmaceutical composition | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MY171135A (en) | Antibodies specific for tgf-beta | |
| MA38478A1 (fr) | Anticorps anti-pac1 humains | |
| MX2023009856A (es) | Dosificacion optimizada de diaminofenotiazinas en poblaciones. | |
| MA45172B1 (fr) | Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées | |
| EP4285993A3 (fr) | Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine | |
| PH12018502451A1 (en) | Brain delivery protein | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
| WO2012173781A3 (fr) | Méthodes de traitement des troubles du métabolisme du glucose | |
| EP3908308A4 (fr) | Analogues de petites molécules de la protéine e4orf1 dans le traitement et la prévention de troubles métaboliques | |
| MA37640A1 (fr) | Protéines du facteur de croissance des fibroblastes 21 | |
| TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders | |
| ATE535246T1 (de) | Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems | |
| UA92465C2 (ru) | Терапевтические применения ингибиторов rtp801 |